Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Mladek

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Cancer Research|December 25, 2002
Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapyJeffrey S Eshleman, Brett L Carlson, Ann C Mladek, et al.
Journal of Neuro-Oncology|October 12, 2012
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cellsAditi Nadkarni, Meena Shrivastav, Ann C Mladek, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 10, 2019
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain MetastasesGautham Gampa, Minjee Kim, Afroz S Mohammad, et al.
Neoplasia (New York, N.Y.)|October 26, 2005
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cellsRavi D Rao, Ann C Mladek, Jeffrey D Lamont, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2022
Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain MetastasesSurabhi Talele, Wenjuan Zhang, Ju-Hee Oh, et al.
Molecular Cancer Therapeutics|October 30, 2014
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowthYulian P Ramirez, Ann C Mladek, Roger M Phillips, et al.
Frontiers in Oncology|February 7, 2019
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular HeterogeneityShiv K Gupta, Emily J Smith, Ann C Mladek, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2021
Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain TumorMinjee Kim, Shiv K Gupta, Wenjuan Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2014
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenograftsShiv K Gupta, Ann C Mladek, Brett L Carlson, et al.
Molecular Cancer Therapeutics|October 13, 2023
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in GlioblastomaWenjuan Zhang, Rachael A Vaubel, Ju-Hee Oh, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Cancer Research|December 25, 2002
Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapyJeffrey S Eshleman, Brett L Carlson, Ann C Mladek, et al.
Journal of Neuro-Oncology|October 12, 2012
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cellsAditi Nadkarni, Meena Shrivastav, Ann C Mladek, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 10, 2019
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain MetastasesGautham Gampa, Minjee Kim, Afroz S Mohammad, et al.
Neoplasia (New York, N.Y.)|October 26, 2005
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cellsRavi D Rao, Ann C Mladek, Jeffrey D Lamont, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2022
Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain MetastasesSurabhi Talele, Wenjuan Zhang, Ju-Hee Oh, et al.
Molecular Cancer Therapeutics|October 30, 2014
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowthYulian P Ramirez, Ann C Mladek, Roger M Phillips, et al.
Frontiers in Oncology|February 7, 2019
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular HeterogeneityShiv K Gupta, Emily J Smith, Ann C Mladek, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2021
Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain TumorMinjee Kim, Shiv K Gupta, Wenjuan Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2014
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenograftsShiv K Gupta, Ann C Mladek, Brett L Carlson, et al.
Molecular Cancer Therapeutics|October 13, 2023
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in GlioblastomaWenjuan Zhang, Rachael A Vaubel, Ju-Hee Oh, et al.
Pageof 5